The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1783, Issue 5, 2008, Pages 896-903

  Chen, Mengqian ^a   Chen, Li Mei ^a   Lin, Chen Yong ^b   Chai, Karl X ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

ErbB receptor tyrosine kinase; Extracellular signal regulated kinase; GPI anchor; MT SP1; PRSS8; Transmembrane glycoprotein

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIPTASE; PROSTASIN; SERINE PROTEINASE;

ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION;

CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; EPITHELIAL CELLS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERINE ENDOPEPTIDASES; TYROSINE;

EID: 41949136687     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2007.10.019     Document Type: Article

References (50)

1. Chen L.M., Skinner M.L., Kauffman S.W., Chao J., Chao L., Thaler C.D., and Chai K.X. Prostasin is a glycosylphosphatidylinositol-anchored active serine protease. J. Biol. Chem. 276 (2001) 21434-21442
2. Fan B., Wu T.D., Li W., and Kirchhofer D. Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J. Biol. Chem. 280 (2005) 34513-34520
3. Yu J.X., Chao L., and Chao J. Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA. J. Biol. Chem. 270 (1995) 13483-13489
4. Adachi M., Kitamura K., Miyoshi T., Narikiyo T., Iwashita K., Shiraishi N., Nonoguchi H., and Tomita K. Activation of epithelial sodium channels by prostasin in Xenopus oocytes. J. Am. Soc. Nephrol. 12 (2001) 1114-1121
5. Vallet V., Chraibi A., Gaeggeler H.P., Horisberger J.D., and Rossier B.C. An epithelial serine protease activates the amiloride-sensitive sodium channel. Nature 389 (1997) 607-610
6. Vuagniaux G., Vallet V., Jaeger N.F., Pfister C., Bens M., Farman N., Courtois-Coutry N., Vandewalle A., Rossier B.C., and Hummler E. Activation of the amiloride-sensitive epithelial sodium channel by the serine protease mCAP1 expressed in a mouse cortical collecting duct cell line. J. Am. Soc. Nephrol. 11 (2000) 828-834
7. Chen L.M., Hodge G.B., Guarda L.A., Welch J.L., Greenberg N.M., and Chai K.X. Down-regulation of prostasin serine protease: a potential invasion suppressor in prostate cancer. Prostate 48 (2001) 93-103
8. Chen L.M., and Chai K.X. Prostasin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter DNA methylation. Int. J. Cancer 97 (2002) 323-329
9. Leyvraz C., Charles R.P., Rubera I., Guitard M., Rotman S., Breiden B., Sandhoff K., and Hummler E. The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J. Cell Biol. 170 (2005) 487-496
10. Chen L.M., Wang C., Chen M., Marcello M.R., Chao J., Chao L., and Chai K.X. Prostasin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation. Am. J. Physiol. Renal Physiol. 291 (2006) F567-F577
11. Chen M., Chen L.M., and Chai K.X. Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG. Prostate 66 (2006) 911-920
12. Chen M., Chen L.M., and Chai K.X. Mechanisms of sterol regulatory element-binding protein-2 (SREBP-2) regulation of human prostasin gene expression. Biochem. Biophys. Res. Commun. 346 (2006) 1245-1253
13. List K., Hobson J.P., Molinolo A., and Bugge T.H. Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase. J. Cell. Physiol. 213 (2007) 237-245
14. Netzel-Arnett S., Currie B.M., Szabo R., Lin C.Y., Chen L.M., Chai K.X., Antalis T.M., Bugge T.H., and List K. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J. Biol. Chem. 281 (2006) 32941-32945
15. Chen L.M., Zhang X., and Chai K.X. Regulation of prostasin expression and function in the prostate. Prostate 59 (2004) 1-12
16. Takahashi S., Suzuki S., Inaguma S., Ikeda Y., Cho Y.M., Hayashi N., Inoue T., Sugimura Y., Nishiyama N., Fujita T., Chao J., Ushijima T., and Shirai T. Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers. Prostate 54 (2003) 187-193
17. Chen M., Fu Y.Y., Lin C.Y., Chen L.M., and Chai K.X. Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3. Biochim. Biophys. Acta 1773 (2007) 1133-1140
18. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137
19. Wells A. EGF receptor. Int. J. Biochem. Cell Biol. 31 (1999) 637-643
20. Bellezza I., Bracarda S., Caserta C., and Minelli A. Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro. Mol. Genet. Metab. 88 (2006) 114-122
21. Lo H.W., Hsu S.C., and Hung M.C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res.Treat. 95 (2006) 211-218
22. Normanno N., De L.A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De F.G., Caponigro F., and Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366 (2006) 2-16
23. Ahmed S.M., and Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 11 (2006) 687-692
24. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 Suppl 4 (2001) S9-S15
25. Morris G.L., and Dodd J.G. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J. Urol. 143 (1990) 1272-1274
26. Ching K.Z., Ramsey E., Pettigrew N., D'Cunha R., Jason M., and Dodd J.G. Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol. Cell. Biochem. 126 (1993) 151-158
27. Skogseth H., Larsson E., and Halgunset J. The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase. APMIS 114 (2006) 61-66
28. Skogseth H., Larsson E., and Halgunset J. Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells. APMIS 113 (2005) 332-339
29. Yates C.C., Shepard C.R., Stolz D.B., and Wells A. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br. J. Cancer 96 (2007) 1246-1252
30. El Sheikh S.S., Domin J., Abel P., Stamp G., and Lalani e.-N. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 6 (2004) 846-853
31. Oberst M.D., Chen L.Y., Kiyomiya K., Williams C.A., Lee M.S., Johnson M.D., Dickson R.B., and Lin C.Y. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am. J. Physiol. Cell Physiol. 289 (2005) C462-C470
32. Jones S.M., Foreman S.K., Shank B.B., and Kurten R.C. EGF receptor downregulation depends on a trafficking motif in the distal tyrosine kinase domain. Am. J. Physiol. Cell Physiol. 282 (2002) C420-C433
33. Stern K.A., Visser Smit G.D., Place T.L., Winistorfer S., Piper R.C., and Lill N.L. Epidermal growth factor receptor fate is controlled by Hrs tyrosine phosphorylation sites that regulate Hrs degradation. Mol. Cell. Biol. 27 (2007) 888-898
34. Vallet V., Pfister C., Loffing J., and Rossier B.C. Cell-surface expression of the channel activating protease xCAP-1 is required for activation of ENaC in the Xenopus oocyte. J. Am. Soc. Nephrol. 13 (2002) 588-594
35. Li B., Yuan M., Kim I.A., Chang C.M., Bernhard E.J., and Shu H.K. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23 (2004) 4594-4602
36. Hobert M., and Carlin C. Cytoplasmic juxtamembrane domain of the human EGF receptor is required for basolateral localization in MDCK cells. J. Cell. Physiol. 162 (1995) 434-446
37. Mok S.C., Chao J., Skates S., Wong K., Yiu G.K., Muto M.G., Berkowitz R.S., and Cramer D.W. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl. Cancer Inst. 93 (2001) 1458-1464
38. Jin J.S., Cheng T.F., Tsai W.C., Sheu L.F., Chiang H., and Yu C.P. Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters. Histol. Histopathol. 22 (2007) 305-309
39. Kang J.Y., Dolled-Filhart M., Ocal I.T., Singh B., Lin C.Y., Dickson R.B., Rimm D.L., and Camp R.L. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63 (2003) 1101-1105
40. Welm A.L., Sneddon J.B., Taylor C., Nuyten D.S., van de Vijver M.J., Hasegawa B.H., and Bishop J.M. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 7570-7575
41. Rusnak D.W., Alligood K.J., Mullin R.J., Spehar G.M., Arenas-Elliott C., Martin A.M., Degenhardt Y., Rudolph S.K., Haws Jr. T.F., Hudson-Curtis B.L., and Gilmer T.M. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif. 40 (2007) 580-594
42. Rotterud R., Fossa S.D., and Nesland J.M. Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium. Histol. Histopathol 22 (2007) 349-363
43. Christensen M.E. The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan. Med. Bull. 45 (1998) 121-134
44. Repertinger S.K., Campagnaro E., Fuhrman J., El-Abaseri T., Yuspa S.H., and Hansen L.A. EGFR enhances early healing after cutaneous incisional wounding. J. Invest. Dermatol. 123 (2004) 982-989
45. Bonaccorsi L., Nosi D., Muratori M., Formigli L., Forti G., and Baldi E. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J. Mol. Endocrinol. 38 (2007) 51-66
46. Carpenter G. The EGF receptor: a nexus for trafficking and signaling. Bioessays 22 (2000) 697-707
47. Johannessen L.E., Haugen K.E., Ostvold A.C., Stang E., and Madshus I.H. Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms. Biochem. J. 356 (2001) 87-96
48. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer 37 Suppl 4 (2001) S16-S22
49. Hildebrandt B., le Coutre P., Nicolaou A., Köble K., Riess H., and Dörken B. Cetuximab: appraisal of a novel drug against colorectal cancer. Recent Results Cancer Res. 176 (2007) 135-143
50. Merlano M., and Garrone O. Treatment of advanced head and neck cancer with cetuximab. Int. J. Biol. Markers 22 (2007) S71-S76